Acorda Therapeutics, Inc. (ACOR)
Price:
0.66 USD
( - -0.21 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Intra-Cellular Therapies, Inc.
VALUE SCORE:
0
2nd position
Neurocrine Biosciences, Inc.
VALUE SCORE:
9
The best
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
NEWS
Acorda Therapeutics Announces Delisting from Nasdaq
businesswire.com
2024-04-15 17:03:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.
Acorda Therapeutics Announces Nasdaq Delisting Notification
businesswire.com
2024-04-03 17:30:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
investorplace.com
2024-04-02 08:57:50Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will have Merz Therapeutics acquire substantially all of the company's assets for $185 million.
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
marketwatch.com
2024-04-01 19:31:00Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
businesswire.com
2024-04-01 18:35:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
businesswire.com
2024-01-11 08:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
seekingalpha.com
2023-11-13 17:43:09Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
businesswire.com
2023-11-13 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
businesswire.com
2023-11-06 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
businesswire.com
2023-08-08 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
businesswire.com
2023-08-02 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
Tom Burns Elected to the Acorda Therapeutics Board of Directors
businesswire.com
2023-06-28 17:08:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
businesswire.com
2023-06-26 08:23:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
businesswire.com
2023-06-26 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
businesswire.com
2023-06-02 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
businesswire.com
2023-05-31 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.
No data to display
Acorda Therapeutics Announces Delisting from Nasdaq
businesswire.com
2024-04-15 17:03:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.
Acorda Therapeutics Announces Nasdaq Delisting Notification
businesswire.com
2024-04-03 17:30:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
investorplace.com
2024-04-02 08:57:50Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will have Merz Therapeutics acquire substantially all of the company's assets for $185 million.
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
marketwatch.com
2024-04-01 19:31:00Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
businesswire.com
2024-04-01 18:35:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
businesswire.com
2024-01-11 08:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
seekingalpha.com
2023-11-13 17:43:09Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
businesswire.com
2023-11-13 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
businesswire.com
2023-11-06 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
businesswire.com
2023-08-08 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
businesswire.com
2023-08-02 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
Tom Burns Elected to the Acorda Therapeutics Board of Directors
businesswire.com
2023-06-28 17:08:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
businesswire.com
2023-06-26 08:23:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
businesswire.com
2023-06-26 08:00:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
businesswire.com
2023-06-02 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
businesswire.com
2023-05-31 16:01:00PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.